Abstract Hypokalemic periodic paralysis (HypoPP) is an autosomal dominant disorder which is characterized by periodic attacks of muscle weakness associated with a decrease in the serum potassium level. The skeletal muscle calcium channel α-subunit gene CACNA1S is a major disease-causing gene for HypoPP, however, only three specific HypoPP-causing mutations, Arg528His, Arg1,239His and Arg1,239Gly, have been identified in CACNA1S to date. In this study, we studied a four-generation Chinese family with HypoPP with 43 living members and 19 affected individuals. Linkage analysis showed that the causative mutation in the family is linked to the CACNA1S gene with a LOD score of 6.7. DNA sequence analysis revealed a heterozygous C to G transition at nucleotide 1,582, resulting in a novel 1,582C→G (Arg528Gly) mutation. The Arg528Gly mutation co-segregated with all affected individuals in the family, and was not present in 200 matched normal controls. The penetrance of the Arg528Gly mutation was complete in male mutation carriers, however, a reduced penetrance of 83% (10/12) was observed in female carriers. No differences were detected for age-at-onset and severity of the disease (frequency of symptomatic attacks per year) between male and female patients. Oral intake of KCl is effective in blocking the symptomatic attacks. This study identifies a novel Arg528Gly mutation in the CACNA1S
Introduction
Hypokalemic periodic paralysis (HypoPP) and hyperkalemic periodic paralysis (HyperPP) are two genetic muscle disorders that are inherited in an autosomal dominant fashion, and present with clinically similar features of episodic flaccid generalized weakness [1] . An important clinical difference between the two entities is the trigger of the attacks of weakness. They can be distinguished by the changes in serum potassium levels before and during paralytic attacks. HyperPP can be provoked by oral potassium administration, whereas a low concentration of serum potassium triggers HypoPP. Co-occurrence of myotonia has been reported in HyperPP patients, but not in HypoPP patients [1] .
HypoPP is the most common form of periodic paralysis in man, although it is still a rare disease with a prevalence of about 0.4 in 100,000 [2] . Familial HypoPP is a muscle disease characterized by periodic attacks of partial or total muscle weakness associated with a decrease in serum potassium. Two disease-causing genes have been identified for HypoPP, both of which encode ion channels, including the human skeletal muscle dihydropyridine-sensitive calcium channel α1-subunit gene CACNA1S [3] and the skeletal muscle sodium channel α-subunit gene SCN4A [4, 5] . A voltage-gated potassium channel β-subunit gene, KCNE3, was claimed as a HypoPP gene with the identification of one variant (Arg83His) in two families [6] , but recent studies suggest that Arg83His may be a benign polymorphic variant that is not associated with HypoPP [7, 8] .
The skeletal muscle calcium channel CACNA1S mediates excitation-contraction coupling. Calcium influx through CACNA1S triggers the local release of a large amount of calcium (Ca 2+ sparks) from the intracellular calcium release channel, resulting in muscle contraction. CACNA1S is composed of four homologous domains (DI-DIV), each of them consisting of six transmembrane segments (S1-S6) [9] . Three specific mutations have been identified in the CACNA1S gene in families with HypoPP: Arg528His in DIIS4, and Arg1,239His and Arg123Gly in DIVS4 [3, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . These mutations are all missense mutations where an arginine residue is replaced by either a histidine or sometimes a glycine residue. These mutations are all located in the voltage sensor of the transmembrane segment of the calcium channel. Mutations in CACNA1S account for approximately 70% of HypoPP cases [12] . An Arg1,086His mutation in the loop between DIII and DIV of CACNA1S has also been linked to malignant hyperthermia [20, 21] .
In this study, we identified and characterized a large Chinese family with HypoPP, with 43 family members (19 with a clinical diagnosis of HypoPP). We used linkage analysis to map the disease-causing gene in this family to the CACNA1S gene on chromosome 1q31-32, and further studies identified a novel mutation, 1,582C→G (Arg528-Gly), in CACNA1S. Genotype-phenotype correlation studies were carried out to characterize the clinical characteristics associated with the Arg528Gly mutation.
Materials and methods

Study subjects and isolation of genomic DNA
The study participants were identified and enrolled at Huazhong University of Science and Technology Union Hospital. Informed consent was obtained from the participants in accordance with the study protocols approved by the Ethics Committee of Huazhong University of Science and Technology. Detailed records on their medical history, physical examinations and blood potassium levels were obtained. The diagnosis of HypoPP was made on the basis of symptoms, physical signs and the blood potassium level.
Peripheral blood was collected from all participants. Genomic DNA was isolated from the whole blood with the DNA isolation kit for mammalian blood (Roche Diagnostics, Indianapolis, Ind.).
Linkage analysis
Linkage analysis was carried out as described [22] [23] [24] . Three polymorphic microsatellite markers, D1S413, D17S944 and D11S1314, were selected from the ABI PRISM Linkage Mapping Set MD10 panel for linkage analysis. These markers are closely linked to the two known HypoPP genes CACNA1S, SCN4A and the KCNE3 candiate gene. Markers were genotyped using an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, Calif.) at Huazhong University of Science and Technology Human Genome Research Center. Genotypes were analyzed using the GeneMapper 2 Software program (Applied Biosystems). Pairwise logarithm of the odds (LOD) scores were calculated with the Linkage Package 5.2 program assuming an autosomal dominant inheritance pattern, a gene frequency of 0.001, a penetrance rate of 80%, and an allele frequency of 1/n, where n equals the number of alleles observed [22] [23] [24] .
Mutation screening
Mutation screening was carried out using direct DNA sequence analysis. CACNA1S exons were PCR-amplified. PCR was performed in 25 μl of standard PCR buffer containing 1.5 mM MgCl 2 , 0.2 mM of each dNTP, 0.5 μM of each primer, 1 U of Taq polymerase, and 50 ng of DNA. The amplification program was an initial 3-min denaturation at 94°C, followed by 35 cycles of 30 s at 94°C, 30 s at 56°C, 1 min at 72°C, and a final 7-min extension step at 72°C. The PCR products were extracted using the QIAquick Gel Extraction Kit (Qiagen, Valencia, Calif.), and sequenced with both forward and reverse primers. DNA sequencing analysis was performed using the BigDye Terminator Cycle Sequencing v3.1 kit and an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
RFLP analysis
Mutation 1,582C→G (Arg528Gly) disrupts an MspA1 I restriction site, which allowed us to perform RFLP analysis to confirm the mutation and to test whether the mutation co-segregates with the disease in the family. We PCR-amplified exon 11 containing the Arg528Gly mutation from all members of the family as well as 200 unrelated healthy Chinese individuals of Han nationality. The 364-bp PCR product was digested with 1 U of MspA1 I (New England Biolabs) at 37°C overnight. The resulting digestion products were separated on a 2.5% agarose gel.
Results
We identified a large Chinese family with 43 living individuals in four generations (Fig. 1) . In the family, 19 members were clinically diagnosed as affected with HypoPP. The proband is a 53-year-old male (II-1 in Fig. 1 ) who experienced the first total muscle weakness attack at the age of 16 years. The attacks usually occur after excessive intake of carbohydrate-rich meals, several hours following strenuous exercise, after sudden exposure to cold, glucose perfusion, and alcohol consumption. His attacks occurred more frequently at a younger age, and became less frequent with advancing age. His blood potassium level was low and the symptoms could be relieved with potassium chloride. His serum potassium levels were 2.3 mmol/l before the attacks and 2.95 mmol/l after relief with KCl.
Similar clinical features were detected in the other 18 affected family members. The age of onset and the frequency of HypoPP attacks are shown in Table 1 for each affected individual in the family. The frequency and severity of attacks and the age of onset vary from patient to patient. The age of onset ranged from 3 to 23 years in females and from 16 to 20 years in males ( Table 1 ). The attacks became less frequent after 40 years of age and disappeared after 60. The frequency of attacks varied from patient to patient, ranging from six times to 300 times per year ( Table 1 ). The duration of the attacks was from 2 h to 2 days. Attacks commonly started in the second half of the night; awakening the patient who was unable to move, and the symptoms could be relieved only with the intake of potassium chloride salt. No significant differences of ageat-onset and the frequency of attacks were identified between males and females (Table 2) . To identify the molecular basis of HypoPP in this family, we carried out linkage analysis for two genes identified as being involved in HypoPP, CACNA1S on chromosome 1q31-32 and SCN4A on 17q23.2-25.3, and also the KCNE3 candidate gene on 11q13-24. Detection of multiple obligate recombinants (affected individuals carrying the normal allele) excluded SCN4A and KCNE3 as the causative gene in the Chinese HypoPP family. Co-segregation of marker D1S413 close to CACNA1S with all affected individuals in the family and a LOD score of 6.70 between the marker and disease suggest that the disease gene in the family is the CACNA1S gene.
Direct sequence analysis of DNA from the proband revealed a heterozygous C to G transition at nucleotide 1,582 of CACNA1S, which results in a substitution of a highly conserved, positively charged amino acid arginine with a neutral glycine residue at codon 528, 1,582C→G (Arg528-Gly) (Fig. 2a) . Mutation Arg528Gly is located in the transmembrane segment S4 of domain II, a critical region serving as the voltage sensor of the channel and regulating the activation of the calcium channel. Amino acid residue R528 is evolutionally conserved from C. elegans to humans (Fig. 2b) . Detection of mutation Arg528Gly was further confirmed by RFLP analysis showing the presence of both the wild type allele (252 and 112 bp bands) and the mutant allele (364 bp band) (proband III-1, Fig. 3) . RFLP results showed that all affected members in the family carried the Arg528-Gly mutation, but the mutation was not present in 200 normal controls (Fig. 3) . All normal individuals except two young female individuals, III-1 and III-3, in the family do not carry the Arg528Gly mutation (Fig. 3) . Identification of two normal individuals (III-1 and III-3) who carry the Arg528Gly mutation suggests reduced penetrance of the mutation in the female patient population.
Discussion
In this study, we present a novel mutation, 1,582C→G (Arg528Gly), in the skeletal muscle calcium channel gene, CACNA1S, that causes the autosomal dominant muscle disorder HypoPP in a large Chinese family. Although CACNA1S mutations are considered to be responsible for the majority of HypoPP cases (70%), only three diseasecausing mutations have been identified, Arg528His, Arg1, 239His and Arg1,239Gly. Previously, the arginine residue at codon 1,239 was found to be frequently mutated to either a histidine or glycine residue, but only a mutation to a histidine residue from the arginine at codon 528 was detected. With the identification of the Arg528Gly mutation, our results suggest that Arg528 can also be mutated to a glycine residue. Furthermore, since both Arg528His and Arg528Gly mutations can be evidenced by the loss of the MspA1 I restriction site, both mutations should be considered when screening HypoPP patients using RFLP analysis with this enzyme.
Mutation Arg528Gly co-segregates with the disease in a large family with 19 HypoPP patients, and does not occur in 200 normal controls. The arginine residue at codon 528 is highly conserved from C. elegans to humans, and is located in the critical voltage-sensor domain of the calcium channel. Together with the finding that mutation Arg528His at the same location also causes HypoPP, these results strongly support the conclusion that mutation Arg528Gly is a disease-causing mutation.
The penetrance rate is 100% (9/9) in the male patients and 83.3% (10/12) in the female patients (Table 2) . Recently, a Japanese boy with HypoPP was found to carry the Arg528His mutation in CACNA1S, but his mother and grandmother are clinically normal even though they are mutation carriers [16] . All these results suggest that there is a gender difference for the mutation penetrance of HypoPP. The molecular mechanism for the gender difference in the penetrance of this disease is unknown.
The functional effect of the Arg528Gly mutation on the skeletal calcium channel is not known. We speculate that the mutation may act similarly to the Arg528His mutation and lead to reduction of the L-type calcium current amplitude or density and affect the voltage dependence of channel activation [25, 26] . These effects are expected to result in a lesser calcium influx inside cells, and a failure of generation of Ca 2+ sparks and muscle contraction, resulting in HypoPP. However, it is equally possible that the Arg528 Gly mutation may act differently from the Arg528His mutation. Future electrophysiological characterization of the Arg528Gly mutation will test these hypotheses and provide insights into the mechanism underlying the pathogenesis of HypoPP. Fig. 3 Mutation Arg528Gly of the CACNA1S gene co-segregates with HypoPP in the family. Marker 100-bp molecular weight ladder/ marker (Invitrogen), N normal phenotype, P affected phenotype. The sample lanes are labeled with the unique identification numbers for each individual in the Chinese family with HypoPP as in Fig. 1 , e.g. I-1 is for individual 1 at generation I in Fig. 1 . The Arg528Gly mutation abolishes an MspA1 I site. The wild type PCR product can be cut by MspA1 I, yielding two shorter DNA fragments of 252 and 112 bp. Normal family members display two 252 and 112 bp bands except for the two female individuals III-1 and III-3 (marked with N*) who show reduced penetrance. The PCR fragment containing mutation Arg528Gly cannot be cut by the enzyme, resulting in only one DNA fragment of 364 bp. All affected individuals in the family are heterozygous for the Arg528Gly mutation (three fragments: 364, 252, and 112 bp). the PCR primers used were: 528-1 forward, 5′-AAGGCTGGGAGTCAGGAGAAG-3′ and 528-1 reverse, 5′-ATGAGATGGGTGTAGACCAGAC-3′
